Bristol-Myers Squibb Co
(LIM:BMY)
$
56.98
(0%)
Market Cap: 115.79 Bil
Enterprise Value: 151.76 Bil
PE Ratio: 15.93
PB Ratio: 5.77
GF Score: 57/100 Bristol-Myers Squibb Co at Guggenheim Partners Healthcare Talks Oncology Days Transcript
Feb 12, 2021 / 05:00PM GMT
Seamus Christopher Fernandez
Guggenheim Securities, LLC, Research Division - Senior Analyst of Global Pharmaceuticals
Thanks, everybody. Good afternoon. Thanks for joining us for a fireside chat session with Bristol-Myers Squibb. I'm Seamus Fernandez, Guggenheim's global biopharma analyst. We're joined today by Chris Boerner, Chief Commercialization Officer of Bristol-Myers Squibb. And obviously, we have a brief (inaudible) time here. I do apologize we're starting a touch late just because my Internet connection was unstable. So we're using the support of the global network at this point. So...
Christopher S. Boerner
Bristol-Myers Squibb Company - Executive VP & Chief Commercialization Officer
Welcome to the world we live in.
Questions & Answers
Seamus Christopher Fernandez
Guggenheim Securities, LLC, Research Division - Senior Analyst of Global Pharmaceuticals
Exactly. So thanks again, everybody, for joining us. We do have a short time. So Bristol's breadth in oncology is obviously quite
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |

30-Day 100% money back guarantee
Subscription fee may be tax deductible.
Excellent 

4.6 out of 5
Trustpilot